Lead Product(s): 6-Hydroxymethylacylfulvene
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 16, 2020
Funds is directed towards Lantern Pharma's most advanced candidate is LP-100, a potential treatment for prostate cancer that is in a Phase 2 trial with out-licensing partner Oncology Venture.